DaVita Inc. (NYSE:DVA) Receives Consensus Rating of “Hold” from Brokerages

Shares of DaVita Inc. (NYSE:DVA) have received an average recommendation of “Hold” from the five analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $161.80.

A number of equities analysts have issued reports on the stock. Barclays boosted their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Truist Financial increased their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Finally, Bank of America boosted their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. The trade was a 5.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DVA. Transcendent Capital Group LLC bought a new position in shares of DaVita during the third quarter valued at approximately $25,000. Blue Trust Inc. raised its stake in DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after buying an additional 78 shares during the last quarter. Family Firm Inc. bought a new stake in DaVita in the second quarter worth $43,000. Versant Capital Management Inc boosted its holdings in DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after acquiring an additional 155 shares in the last quarter. Finally, Friedenthal Financial purchased a new stake in shares of DaVita in the second quarter worth $48,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Trading Down 1.5 %

Shares of DVA stock opened at $163.74 on Tuesday. The business has a 50-day moving average of $158.57 and a 200 day moving average of $149.48. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita has a 1-year low of $103.40 and a 1-year high of $169.51. The stock has a market capitalization of $13.43 billion, a PE ratio of 17.66, a P/E/G ratio of 0.94 and a beta of 0.90.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same period last year, the company posted $2.85 EPS. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that DaVita will post 9.71 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.